Financial Performance - Net profit attributable to shareholders rose by 43.20% to CNY 290,641,077.06 for the reporting period [7]. - The company reported a year-to-date net profit of CNY 838,629,574.68, reflecting a 72.20% increase compared to the same period last year [7]. - The net profit attributable to shareholders increased by 72.20% year-on-year, driven by revenue growth from the pharmaceutical segment and real estate project settlements [15]. - Basic earnings per share increased by 43.70% to CNY 1.71 [7]. - The weighted average return on equity improved to 5.83%, up by 0.94% [7]. Revenue Growth - Operating revenue grew by 32.74% to CNY 1,390,398,946.07 for the reporting period [7]. - Revenue from the pharmaceutical segment grew by 41.39%, with net profit increasing by 55.85% [15]. - Operating revenue increased by ¥1.49 billion, a growth of 56.36%, attributed to the pharmaceutical and real estate sectors [16]. - Cash received from sales and services increased by 65.69%, totaling approximately ¥1.75 billion, driven by higher sales in the pharmaceutical and real estate sectors [19]. Asset Management - Total assets increased by 18.07% to CNY 8,679,547,073.47 compared to the end of the previous year [7]. - Net assets attributable to shareholders increased by 15.84% to CNY 5,126,983,335.27 compared to the end of the previous year [7]. - Accounts receivable increased by 72.60%, totaling approximately ¥390.2 million, primarily due to increased revenue from the pharmaceutical company [15]. - Prepayments rose by 272.41%, amounting to approximately ¥766.6 million, mainly due to increased advance payments for relocation by the real estate company [16]. Cash Flow - Net cash flow from operating activities surged by 336.26% to CNY 301,263,696.33 year-to-date [7]. - Cash received from investment activities increased by 85.88%, totaling approximately ¥1.3 billion, primarily from maturing financial products [20]. - Cash paid for fixed assets and other long-term assets increased by 159.32%, amounting to approximately ¥258.2 million, due to prepayments for new factory construction and equipment [20]. Expenses - Operating costs rose by 92.35%, totaling approximately ¥292 million, due to increased revenue in the same sectors [16]. - R&D expenses increased by 46.49%, amounting to approximately ¥82.9 million, reflecting higher investment in the pharmaceutical segment [17]. Non-Recurring Items - Non-recurring gains and losses totaled CNY 20,650,915.42 for the year-to-date [8]. - The company has not reclassified any non-recurring gains and losses as regular gains and losses during the reporting period [9].

Financial Performance - The estimated net profit attributable to shareholders for the first three quarters of 2018 is expected to be between 779 million and 925 million CNY, representing a year-on-year growth of 60% to 90%[3] - The basic earnings per share are projected to be approximately 4.58 to 5.43 CNY, compared to 2.86 CNY in the same period last year[3] - The increase in net profit is primarily due to revenue growth from key pharmaceutical enterprises and an increase in revenue from real estate development projects[5] Reporting and Auditing - The performance forecast has not been audited by a registered accountant[4] - The specific data will be detailed in the company's third-quarter report for 2018[6]